122 related articles for article (PubMed ID: 38266104)
1. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract][Full Text] [Related]
2. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
[TBL] [Abstract][Full Text] [Related]
3. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis.
Kingston D; Schmid MA; Onai N; Obata-Onai A; Baumjohann D; Manz MG
Blood; 2009 Jul; 114(4):835-43. PubMed ID: 19465690
[TBL] [Abstract][Full Text] [Related]
4. Introduction of Human Flt3-L and GM-CSF into Humanized Mice Enhances the Reconstitution and Maturation of Myeloid Dendritic Cells and the Development of Foxp3
Iwabuchi R; Ikeno S; Kobayashi-Ishihara M; Takeyama H; Ato M; Tsunetsugu-Yokota Y; Terahara K
Front Immunol; 2018; 9():1042. PubMed ID: 29892279
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
Smith CC; Levis MJ; Frankfurt O; Pagel JM; Roboz GJ; Stone RM; Wang ES; Severson PL; West BL; Le MH; Kayser S; Lam B; Hsu HH; Zhang C; Bollag G; Perl AE
Blood Adv; 2020 Apr; 4(8):1711-1721. PubMed ID: 32330242
[TBL] [Abstract][Full Text] [Related]
7. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
8. Pexidartinib: First Approval.
Lamb YN
Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity.
Tussiwand R; Onai N; Mazzucchelli L; Manz MG
J Immunol; 2005 Sep; 175(6):3674-80. PubMed ID: 16148112
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-mediated inhibition of dendritic cell development correlates with decreased CD135 expression and increased monocyte/macrophage precursors.
Guerrero AD; Dong MB; Zhao Y; Lau-Kilby A; Tarbell KV
Immunology; 2014 Dec; 143(4):640-50. PubMed ID: 24954893
[TBL] [Abstract][Full Text] [Related]
13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis.
Dunn TN; Cope DI; Tang S; Sirupangi T; Parks SE; Liao Z; Yuan F; Creighton CJ; Masand RP; Alpuing Radilla L; Guan X; Detti L; Monsivais D; Matzuk MM
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38227801
[TBL] [Abstract][Full Text] [Related]
15. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
[TBL] [Abstract][Full Text] [Related]
17. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
18. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
19. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.
Lisovsky M; Estrov Z; Zhang X; Consoli U; Sanchez-Williams G; Snell V; Munker R; Goodacre A; Savchenko V; Andreeff M
Blood; 1996 Nov; 88(10):3987-97. PubMed ID: 8916965
[TBL] [Abstract][Full Text] [Related]
20. Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-Fms.
Rossner MT; McArthur GA; Allen JD; Metcalf D
Cell Growth Differ; 1994 May; 5(5):549-55. PubMed ID: 8049161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
